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Abstract 
AMP-activated protein kinase (AMPK) occurs as heterotrimeric complexes in which a catalytic 
subunit (α1/α2) is bound to one of two β subunits (β1/β2) and one of three γ subunits (γ1/γ2/γ3). 
The ability to selectively activate specific isoforms would be a useful research tool, and a promising 
strategy to combat diseases such as cancer and type 2 diabetes. We report that the AMPK activator 
PT-1 selectively increased the activity of γ1- but not γ3-containing complexes in incubated mouse 
muscle. PT-1 increased the AMPK-dependent phosphorylation of the autophagy-regulating kinase 
ULK1 on Ser555 but not proposed γ3 AMPK substrates such as TBC1D1 Ser231 or ACC2 Ser212 
phosphorylation, nor did PT-1 stimulate glucose transport. Surprisingly, however, in HEK-293 cells 
expressing human γ1, γ2 or γ3, PT-1 activated all three complexes equally. We were unable to 
reproduce previous findings suggesting that PT-1 activates AMPK by direct binding between the 
kinase and auto-inhibitory domains of the α subunit. We show instead that PT-1 activates AMPK 
indirectly by inhibiting the respiratory chain and increasing cellular AMP:ATP and/or ADP:ATP 
ratios. Consistent with this mechanism, PT-1 failed to activate AMPK in HEK-293 cells expressing 
an AMP-insensitive R299G mutant of AMPK-γ1. We propose that the failure of PT-1 to activate 
γ3-containing complexes in muscle is not an intrinsic feature of such complexes, but is because PT-
1 does not increase cellular AMP:ATP ratios in the specific subcellular compartment(s) in which γ3 
complexes are located. 
Summary statement 
PT-1 activates γ1- but not γ3-containing AMPK complexes in mouse muscle, while activating all 
three γ isoforms in HEK-293 cells. PT-1 activates AMPK not by direct binding to α subunits, but 
by inhibiting the respiratory chain and increasing cellular AMP. 
  
Introduction 
The heterotrimeric AMP-activated protein kinase (AMPK) complex, consisting of a catalytic α 
subunit (α1 or α2) in combination with regulatory β (β1 or β2) and γ subunits (γ1, γ2 or γ3), is 
activated by falling cellular energy status in multiple tissues. Once activated, AMPK conserves 
ATP by inhibiting anabolic pathways, while promoting ATP production by stimulating catabolic 
pathways [17;18]. Over the last decade, proof-of-concept studies in rodents have demonstrated that 
chronic administration of AMPK activators, including metformin, the anti-diabetic drug most 
widely prescribed world-wide, offers protection against a variety of disease states such as 
cardiovascular and inflammatory diseases, type 2 diabetes and some forms of cancer 
[5;11;16;37;38].  
Nevertheless, chronic AMPK activation could have deleterious effects in some tissues. This is 
suggested, for example, by the effects of point mutations in the gene encoding the AMPK-γ2 
subunit, which cause increased basal AMPK activity and lead to excessive glycogen accumulation 
and arrhythmias (Wolff-Parkinson-White syndrome) in the heart [1;26]. Although there are 
currently no indications that similar adverse effects are caused by transient pharmacological 
activation of AMPK, one potential strategy to minimize side effects would be to develop drugs that 
specifically target and activate only certain subsets of AMPK heterotrimers. Such drugs would also 
be a useful research tool to assign known and novel targets and physiological functions of AMPK to 
specific AMPK complexes. Several reports of α and β subunit-selective AMPK activators have 
been published [22;27;36;46;49] but a γ subunit-selective compound has not yet been reported. 
In the current study, we set out to test the use of a newly available AMPK activator, PT-1, as a tool 
to study AMPK function in skeletal muscle. PT-1 was proposed to interact directly with AMPK by 
binding in the cleft between the kinase domain (KD) and the auto-inhibitory domains (AID) on the 
α subunits, relieving inhibition of the KD by the AID [32]. We found that PT-1 stimulated AMPK 
heterotrimers associated only with γ1, and not γ3, in contrast to the commonly used activator 
AICAR which activated both isoforms. Consistent with previous findings that the γ3 isoform has a 
function in regulating glucose uptake [2], that process was stimulated by AICAR but not PT-1. 
Despite the apparent isoform selectivity in muscle, when AMPK complexes containing γ1, γ2 or γ3 
were expressed in HEK-293 cells, all three were activated by PT-1. Finally, we re-investigated the 
mechanism by which PT-1 activates AMPK and provide evidence that, contrary to previous 
findings, it does not act by directly binding between the KD and AID, but instead acts indirectly 
(like many other AMPK activators) by inhibiting the respiratory chain and thus increasing cellular 
AMP levels. 
Experimental 
Materials.  
PT-1 was purchased from Tocris Biosciences (USA) and dissolved in DMSO (40 mM stock). 
AICAR was from Toronto Research Chemicals (Canada). Unless otherwise stated, materials were 
from Sigma Aldrich.  
Animals. 
C57BL/6NTac females were purchased from Taconic and housed on a 12h light:12h dark-cycle 
with free access to chow diet (Altromin # 1324, Chr. Pedersen, Denmark) and tap water. The mice 
arrived at age 10-12 weeks and were acclimatized for at least 1 week before experimentation. Wild 
type and muscle-specific dominant-negative kinase-dead α2 (KD) AMPK female mice were 
provided by Morris Birnbaum [30] and have been backcrossed at our facility for >10 generations 
onto the C57BL/6NTac strain. All experiments were carried out on 11-14 wk. old mice. All 
experiments were approved by the Danish Animal Experiments Inspectorate and carried out in 
accordance with the “European Convention for the Protection of Vertebrate Animals Used for 
Experiments and Other Scientific Purposes”.  
Ex vivo muscle incubation.  
Fed mice were anesthetized by intraperitoneal injection of pentobartital/lidocain (6 mg 
pentobarbital sodium and 0.6 mg lidocain/100 g body weight) after which soleus and EDL muscles 
were tied with non-absorbable 4-0 silk suture loops (Look SP116, Surgical Specialities Corporation, 
Reading, PA, USA) at both ends and suspended on adjustable hooks at resting length (1-2 mN 
tension) in ex vivo incubation chambers (Multi Myograph system, Danish Myo-Technology, 
Denmark) at 30°C with constantly 95% O2/5% CO2-bubbled Krebs-Ringer-Henseleit buffer (118.5 
mM NaCl, 24.7 mM NaHCO3, 4.74 mM KCl, 1.18 mM MgSO4·7 H2O, 1.18 mM KH2PO4, 2.5 
mM CaCl2·2 H2O) supplemented with 8 mM mannitol and 2 mM pyruvate (KRH medium). After 
5-10 min of rest, fresh KRH medium was added with either DMSO (amount corresponding to PT-1 
treatment), PT-1, AICAR (2 mM dissolved directly in KRH buffer), or combined PT-1+AICAR. 
After 50 min, the medium was changed to one containing radioactively labeled 3H-2-deoxyglucose 
(0.13 µCi/ml in 1 mM cold 2DG) and mannitol (0.11 µCi/ml in 8 mM cold mannitol) keeping the 
PT-1 and AICAR-treatments the same throughout. At 1h, the muscles were harvested, dipped in 
ice-cold KRH medium, dapped dry on paper and snap-frozen in liquid nitrogen until further 
analyses. 
Muscle immunoblotting and 2 deoxy-glucose (DG) transport analyses.  
Western blotting and 2DG transport were performed on the same muscle lysate. Each muscle was 
trimmed free of connective tissue and sutures in a small container with liquid nitrogen and weighed. 
Afterwards, muscles were homogenized in 300 µl ice-cold lysis buffer (50 mM Tris·HCl, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 5 mM Na4P2O7, 2 mM Na3VO4, 1 mM 
dithiothreitol, 1 mM benzamidine, 1% Nonidet P-40, and 0.5% protease inhibitor cocktail, pH 7.4) 
on a beadmill (Tissuelyser II (Qiagen, USA - 1 min, 30 Hz, maximum 10 muscles/round)), rotated 
end-over-end for 30 min and spun at 13000·g for 20 min to generate lysates. 10 µl was used for 
protein determination (1:10 dilution, Bicinchoninic acid method, Pierce, USA) and 100 µl was 
dissolved in 2 ml of β-scintillation liquid (Ultima Gold, Perkin Elmer, USA) for measurement of 
2DG transport using 14C mannitol to estimate extracellular space using β-scintillation counting. 
Immunoblotting was performed as described previously [23]. The primary antibodies used were 
actin (Sigma-Aldrich, USA, cat#A2668), α2 AMPK (provided by D.G. Hardie), AMPK Thr172 
(Cell Signaling Technology (CST), USA, cat#2531), ACC1 and ACC2 (provided by D.G. Hardie), 
ACC1 Ser79/ACC2 Ser212 (Millipore, USA, cat# 07-303), eEF2 Thr56 (CST cat#2331), Glycogen 
synthase Ser8 (provided by D.G. Hardie [24][19]), p38 MAPK Thr180/Tyr182 (CST cat# 9211), 
Raptor Ser792 (CST cat# 2083), TBC1D1 Ser231 (Millipore cat# 07-2268), TBC1D1 Thr590 (CST 
cat# 6927), TBC1D1 (CST cat#4629) and TBC1D4 (provided by C. MacKintosh, University of 
Dundee, UK [33][18]), ULK1 (Sigma, A7481) ULK1 Ser555 (CST Cat# 5869),. All blots were 
developed on a ChemiDoc MP imaging system (Biorad, Denmark) using enhanced 
chemiluminescence (ECL+, Amersham Biosciences, USA). For stripping and reprobing, membranes 
were placed in stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, Tris HCl pH 6.7) for 1h at 
50°C with occasional agitation, washed and redeveloped with fresh secondary antibody to verify 
strip of primary antibody. Stripped membranes were then blocked and reincubated with new 
primary antibodies overnight. For coomassie-staining, the blots were submerged in coomassie 
brilliant blue G-250 solution for 1 min, washed in distilled water and then left in de-staining 
solution for 10-15 min until a picture using the ChemiDoc MP system.  
AMPK activity assay in mouse lysate 
The measurement of AMPK trimer activities in sequential IPs has been described in detail 
previously (Birk and Wojta 2006; Treebak 2009) and the antibodies used verified for use in mouse 
muscle (Treebak 2009; Treebak 2014). In brief, AMPK activities were measured over 3 days by 
first IP over night of the γ3 subunit to isolate α2/β2/γ3 complex for the activity assay, then IP of the 
α2 subunit to assay α2/β1/γ1 and α2/β2/γ1 activity, then the α1 subunit to measure α1/β1/γ1 and 
α1/β2/γ1 from activity.  No detectable activity associates with γ2 AMPK in mouse or human 
skeletal muscle (Birk 2006; Treebak 2009). 
 Generation of Stable Cell Lines. 
DNAs encoding full-length human AMPK-γ isoforms were amplified and cloned into the 
pcDNA5/FRT/TO plasmid (Invitrogen). T-Rex HEK-293 cells containing a single FRT site 
(Invitrogen) were transfected with Fugene6 (Promega) using the plasmids POG44 and 
pcDND5/FRT/TO/gamma at a ratio of 9:1. Plates were trypsinised 48 hr after transfection and re-
plated in media containing 200 and 15 µg/ml hygromycin B and blasticidin respectively. The 
medium was replaced every 3 days until foci could be identified, and individual foci were then 
selected and expanded. Protein expression was induced by addition of 1 µg/ml of tetracycline for 48 
hr. The expression of FLAG-tagged γ isoforms was checked by Western blotting using anti-FLAG 
antibodies.  
Culture and treatment of cells. 
HEK-293 cells stably expressing γ1, γ2 or γ3 were grown for 48 hr in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 1 g/L glucose, 10% (v/v) tetracycline-free foetal bovine serum, 100 
U/ml penicillin, 100 µg/ml streptomycin and 200 µg/ml hygromicin B, 15 µg/ml blasticidin and 1 
µg/ml tetracycline. The cells were then washed into the above media without foetal bovine serum 
for 16 hr. Cells were treated for 1 hr, rapidly lysed [19] and lysates stored at -80°C until use.  
Cell culture assay of AMPK. 
AMPK was assayed using either AMARA or SAMS peptide as described previously [9;19][1, 2]. 
AMPK from cell lysates was assayed in immunoprecipitates made using EZview Red anti-flag M2 
affinity gel (Sigma). Truncated AMPK-α1 protein (residues 1-312 and 1-335, see below) was 
maximally phosphorylated with saturating amounts of CaMKKβ, before being assayed in the 
presence of increasing concentrations of PT1. Rat liver AMPK was purified as described [20]. 
Cell culture immunoprecipitation, SDS-PAGE and western blotting. 
Lysates were immunoprecipitated using EZview Red anti-flag M2 affinity gel (Sigma). The beads 
were washed 2x in IP buffer (50 mM Na Hepes, 1 mM DTT pH 7.4, the supernatant was removed 
and the beads resuspended in SDS-PAGE sample buffer. The beads were incubated at 100°C for 20 
min and the supernatant analysed by SDS-PAGE and Western blotting as described. The anti-pT172, 
AMPK-α and AMPK-β1 antibodies were from Cell Signaling, the anti-FLAG antibody from Sigma, 
and all other antibodies were made in-house [6;44]. 
Expression and purification of bacterial proteins. 
Truncated rat AMPK-α1 kinase domain constructs (residues 1-312 and 1-335) were produced as 
described [13]. Plasmids were transfected into BL21 (DE3) competent cells and expressed in LB 
media until the absorbance at 600 nm was ≈0.6, when protein expression was induced with IPTG. 
Cells were harvested by centrifugation, lysed using a pestle and mortar and resuspended in 50 mM 
Tris pH 8.0, 500 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT and protease inhibitor tablets 
(Roche). The lysates were clarified by centrifugation (30,000 rpm; 30 min; 4°C) and the 
supernatants applied to GST FF columns (1 ml, Life Science). After washing, protein was eluted in 
buffer containing 20 mM glutathione.  
Other procedures. 
Measurement of whole cell oxygen uptake and estimation of cellular ADP:ATP ratio was as 
described [21]. 
 
Statistical analyses.  
One or 2-way ANOVA was performed as appropriate (Sigmaplot 12.5). When significant, post hoc 
tests were used to control for multiple comparisons as indicated in the figure legends. The 
significance level was set at p<0.05.  
RESULTS 
PT-1 activates AMPK, but does not increase glucose uptake in mouse muscle 
incubated ex vivo 
In cultured L6 myotubes, PT-1 at 20-80 µM was previously reported to dose-dependently increase 
phosphorylation of Thr172 on AMPK [32]. In our ex vivo mouse muscle incubation system, we 
initially tested the effect of increasing doses of PT-1 for 1h on Thr172 phosphorylation in the 
oxidative, type I fiber-enriched soleus muscle, and the more glycolytic type II fiber-enriched EDL 
muscle. We observed a consistent 2-3-fold increase in phosphorylation by 100 µM PT-1 in both 
muscle types (Fig. 1A). The AMPK activator AICAR, which is converted to the AMP mimetic 
ZMP within the cells [7], increases glucose transport in isolated mouse muscle in an AMPK-
dependent manner in various transgenic mouse models [2;25;39]. To test if this was also the case 
for PT-1, muscles from wild type mice or mice with muscle-specific expression of a kinase-inactive, 
dominant-negative AMPK-α2 mutant (KD AMPK) were incubated with PT-1. PT-1 clearly 
increased AMPK Thr172 phosphorylation (Fig. 1B) but, unexpectedly, slightly suppressed glucose 
transport (Fig. 1C). Total AMPK α2 expression on average was respectively 2.7±0.18 and 2.9±0.01 
times higher in the KD AMPK soleus and EDL muscles compared to wild type (representative blots 
shown but quantifications not shown).  
To directly compare the effect of AICAR and PT-1, mouse muscles were stimulated ex vivo with 
either one or both compounds combined. AMPK Thr172 phosphorylation was increased by PT-1 in 
both soleus and EDL muscle (Fig. 2A). Interestingly, AICAR increased the phosphorylation of 
Ser212 on the endogenous AMPK substrate ACC2, whereas PT-1 did not (Fig. 2B). Another 
AMPK substrate and proposed mediator of the stimulatory effect of AMPK on glucose transport is 
the Rab-GTPase activating protein, TBC1D1. This protein is enriched in mouse EDL muscle [40] 
and was therefore only measured in EDL. Similar to phosphorylation of Ser212 on ACC2, PT-1 
failed to increase phosphorylation of Ser231 on TBC1D1, in contrast to AICAR (Fig. 2C). Another 
phosphorylation site on TBC1D1, Thr590, followed the same pattern as Ser231 in response to PT-1 
and AICAR (Fig. 2D). Glycogen synthase (GS) Ser8 phosphorylation is reduced in α2 AMPK 
knockouts [24] and was recently proposed to be a target of γ1-containing complexes in mouse 
muscle [34]. However, phosphorylation of Ser8 (also referred to as site 2) on GS was not changed 
by either PT-1 or AICAR (Fig. 2E, representative blots in Fig. 2F). The phosphorylation of proteins 
not considered to be part of the AMPK signaling axis in muscle, i.e. Thr180/Tyr182 on p38 MAPK 
and Thr56 on elongation factor-2 (the latter targeted by the Ca2+/calmodulin-dependent kinase 
eEF2K) did not respond to PT-1 or AICAR (quantification not shown, but blots included in Fig 2F). 
As expected, the upper band detected by the TBC1D1 Ser231 antibody aligned with total TBC1D1 
(Fig. 2G) and detection was lost when TBC1D1, but not TBC1D4, was immunodepleted (Fig. 2H). 
In some blots for ACC Ser212 phosphorylation in muscle, we observed a second faint band below 
the strong ACC2 band. When loading high amounts of muscle lysate protein, ACC1 is detectable in 
skeletal muscle (Fig. 2I), making the lower phospho-ACC band likely to stem from ACC1, either 
expressed in muscle fibers or in non-muscle-cell types contaminating the lysate. As a positive 
control for the GS Ser8 phospho-specific antibody, we confirmed that basal phosphorylation was 
reduced in mouse muscles expressing the KD mutant of AMPK (Fig. 2J), as shown previously with 
AMPK-α2 knockout mice [19]. 
Consistent with a role for TBC1D1 in the regulation of glucose transport, AICAR markedly 
stimulated glucose transport (Fig. 3A and 3B) in EDL muscle (which is enriched in the α2β2γ3 
isoform of AMPK [41]), while having only modest effects, which were not statistically significant, 
in soleus muscle. As before (see Fig. 1D), PT-1 had no stimulatory effect on glucose transport and, 
if anything, tended to suppress both basal and AICAR-stimulated glucose transport.  
PT-1 activated γ1 but not γ3 complexes in mouse muscle incubated ex vivo 
The AMPK heterotrimer composition in soleus and EDL muscle of C57BL/6 mice has been 
previously characterized [41]: α2β2γ3 complexes account for <2% and ~20% of total AMPK 
activity in soleus and EDL respectively, with the remaining activity being associated with the γ1 
isoform. Having observed the differential phosphorylation of downstream targets in mouse muscles 
incubated with PT-1 or AICAR, we hypothesized that PT-1 might not be activating all AMPK 
complexes. The kinase activity of specific complexes, prepared by sequential immunoprecipitation 
from lysates of muscle treated with PT-1 or AICAR, was therefore measured. This revealed that 
PT-1 increased the activity of γ1-containing complexes (containing either α1, Fig. 4A, or α2, Fig. 
4B) just as effectively as AICAR. However, the activity of the α2β2γ3 complex was increased by 
AICAR, but not PT-1 (Fig. 4C). Surprisingly, whereas the AMPK Thr172 phosphorylation was 
additive when combining PT-1 with AICAR, none of the AMPK activities showed additivity. 
Taken together with the results in the previous section, this suggests that the α2β2γ3 complex, 
rather than any γ1 complex, is the major regulator of phosphorylation of ACC2 and TBC1D1, as 
well as AMPK-mediated glucose transport, in skeletal muscle. They also reveal that PT-1 activates 
γ1 complexes, but not γ3 complexes, in mouse muscle. 
ULK1 Ser555 phosphorylation was AMPK-dependently increased by PT-1  
To identify γ1 AMPK-regulated substrates, we chose to blot for known AMPK sites on ULK1 
Ser555 and Raptor Ser792 in wild type and KD AMPK muscles ± PT-1. PT-1 increased the 
phosphorylation of ULK1 Ser555 AMPK-dependently in soleus (Fig. 4C+D). In EDL, there was no 
ANOVA main-effect (p=0.08) but using a T-test in wild type alone, there was a significant 
difference (Fig. 4C+D). PT-1 had no effect in soleus but caused a small but significant increase in 
Raptor Ser792 in EDL which was not inhibited by KD AMPK expression (Fig 4C+E). Both sites 
responded potently to AICAR, in particular Raptor Ser792 and were strongly inhibited by KD 
AMPK expression during AICAR-stimulation. This suggests that ULK1 is a γ1 AMPK substrate in 
mouse skeletal muscle whereas Raptor Ser792 is likely a γ3 AMPK substrate. 
PT-1 activates AMPK not by binding to the α subunit, but by increasing cellular AMP 
levels 
Since PT-1 has been proposed to activate AMPK by binding to the α subunit in the cleft between 
the KD and the AID [32], the apparent selectivity for the γ subunit isoform was puzzling. We 
therefore re-investigated the mechanism by which PT-1 activates AMPK. We started by testing its 
ability to activate AMPK in cells expressing an AMP-insensitive γ subunit mutant. We have 
previously used this approach [21] with HEK-293 cells stably expressing either wild type γ2 or an 
R531G mutant, a point mutation originally found in humans with Wolff-Parkinson-White syndrome 
[12] that makes AMPK insensitive to AMP or ADP. However, since we were not sure whether PT-
1 would activate γ2 complexes, we constructed new cell lines in which wild type γ1 or an R299G 
mutant (equivalent to R531G in γ2) were expressed in HEK-293 cells from a tetracycline-inducible 
promoter. Characterization of these cells by Western blotting is shown in Fig. 5A. In cells 
expressing wild type γ1 (WT cells), the recombinant FLAG-γ1 had largely replaced the endogenous 
γ1 and also reduced the expression of endogenous γ2. Replacement of the endogenous γ subunits 
was less complete in the cells expressing the R299G mutant (RG cells). The expression of α1, α2, 
β1 and β2 was not significantly affected by the expression of WT γ1 or the RG mutant. 
We next tested the activation of AMPK (immunoprecipitated using anti-FLAG antibody to obviate 
interference from endogenous γ subunits) in WT and RG cells using berberine, an inhibitor of the 
respiratory chain [43][28] that activates AMPK by increasing cellular AMP levels. As found 
previously using mutations in γ2 rather than γ1 [21], berberine activated AMPK in WT cells but 
completely failed to activate AMPK in RG cells (Fig. 5B). When we tested PT-1 in the same cells, 
we found that the activation was greatly reduced in the RG cells although there did appear to be a 
small residual activation at high PT-1 concentrations (Fig. 5C). PT-1 also caused marked increases 
in Thr172 phosphorylation in WT cells, which were reduced or absent in the RG cells (Fig. 5D). 
The results in Fig. 5 showed that the primary mechanism by which PT-1 activated AMPK was 
dependent on the presence of an intact AMP-binding site. To confirm that PT-1 increased cellular 
AMP, we measured cellular ADP:ATP ratios by capillary electrophoresis of perchloric acid extracts, 
and calculated the AMP:ATP ratios by assuming that the adenylate kinase reaction was at 
equilibrium [14]. Fig. 6A showed that increasing concentration of PT-1 in the medium caused 
progressive increases in the ADP:ATP and AMP:ATP ratios, up to a maximum of 2.7-fold in 
ADP:ATP and 7-fold in AMP:ATP with 100 µM PT-1. We also addressed the effect of PT-1 on 
cellular oxygen uptake (Fig. 6B). Concentrations of PT-1 up to 100 µM caused progressive 
decreases in oxygen uptake, although not as great as those caused by 3 mM phenformin. Like the 
effect of phenformin, the effects of high concentrations of PT-1 were not reversed by adding the 
mitochondrial uncoupler, 2-dinitrophenol. 
PT-1 did not activate AMPK in cell-free assays 
PT-1 had originally been isolated from a screen searching for activators of a truncated (1-394) 
human α1 subunit, and was subsequently shown to also activate an intact α1β1γ1 complex, as well 
as a human α1 construct (1-335) containing the KD and AID, but not a construct (1-312) containing 
the KD only [32]. Surprisingly, although we found (as expected [31]) that a 1-312 construct 
was >10-fold more active than a 1-333 construct when both were phosphorylated on Thr172, 
neither was activated significantly by PT1. The only effect we saw was a progressive inhibition by 
PT-1 at concentrations above 10 µM. In agreement with these results, we found that purified, native 
rat liver AMPK was not activated by PT-1, although like the α1 (1-312) construct it was inhibited at 
high concentrations. As positive controls for allosteric activation, rat liver AMPK was activated 4.5-
fold by AMP and 3.2-fold by A-769662 (Fig. 7B). In view of the discrepancies with previous 
reports, we performed chemical analysis of our commercial preparation of PT-1 (see Methods 
section), which confirmed the expected structure. 
PT-1 activates γ1, γ2 and γ3 complexes expressed in HEK-293 cells 
The results in the previous sections supported the idea that PT-1 did not activate AMPK directly by 
binding between the KD and AID, but instead indirectly by inhibiting the respiratory chain. Since 
all of the residues involved in binding of adenine nucleotides to the γ subunit [45] are conserved in 
the sequences of γ1, γ2 and γ3, our findings that PT-1 was a selective activator of γ1 complexes in 
mouse skeletal muscle remained puzzling. To test whether this apparent selectivity was an intrinsic 
feature of the γ subunit isoforms or was specific to skeletal muscle, we generated isogenic HEK-293 
cells expressing tetracycline-inducible FLAG-tagged human γ1, γ2 or γ3 isoforms. Fig. 8A shows 
that, after tetracycline induction, the FLAG-tagged γ subunits partially, but not completely, replaced 
the endogenous γ1 subunit. The expression of endogenous γ1 (which has a higher mobility on SDS-
PAGE than the FLAG-γ1) decreased in the cells expressing FLAG-γ1 and FLAG-γ2, although the 
effect was less obvious in the cells expressing FLAG-γ3, which was expressed at lower levels as 
judged by the anti-FLAG blots. The expression of endogenous γ2 was also slightly decreased in the 
cells expressing FLAG-γ1 and FLAG-γ3, but the expression of endogenous α1, α2, β1, and β2 did 
not change significantly. We next treated tetracycline-induced cells with PT-1 or another AMPK 
activator, phenformin, and immunoprecipitated AMPK using anti-FLAG antibodies prior to kinase 
assay or Western blotting. The Western blots probed with anti-FLAG antibody in Fig. 5B show that 
approximately equal amounts of the FLAG-tagged γ1, γ2 and γ3 complexes (due to variable N-
terminal regions, these isoforms vary markedly in size) were precipitated. However, in contrast to 
the results obtained in skeletal muscle, the kinase assays on FLAG-tagged AMPK isoforms showed 
that PT-1 and phenformin activated γ1, γ2 and γ3 complexes to similar extents. AICAR was not 
used for the HEK-293 cell experiments because it is a poor activator of AMPK in this cell type. 
This was associated in every case with large increases in Thr172 phosphorylation. Since the 
expressed recombinant γ subunits only partially replaced the endogenous γ1 and γ2 subunits in these 
cells, we did not attempt to study the phosphorylation of downstream targets of AMPK. 
DISCUSSION 
Activators that specifically target the regulatory subunits of AMPK hold much promise in 
development of drugs targeted against human disorders, and as research tools to study AMPK 
function in vivo. Isoform-selective AMPK activation has previously been reported for the α and β 
subunits [22;27;36;46;49] but to our knowledge this is the first study to report a selective activation 
of a subset of AMPK heterotrimers containing the γ1 isoform, at least in skeletal muscle. 
The mechanisms underlying the γ1-specific effects of PT-1 in skeletal muscle remain unclear. PT-1 
was identified by screening a small molecule library [32] against a recombinant, truncated AMPK-
α1 subunit (residues 1-394), which contains the KD and AID plus part of the linker connecting the 
AID to the C-terminal domain. This construct, when phosphorylated on Thr172, was much less 
active than a construct (1-311) containing the KD only [8;32]. The lead compound PT-1 was found 
to increase the activity of the 1-394 construct, which also held true for the equivalent α2 construct 
(1-398), as well as a smaller α1 construct (1-335) containing only the KD and AID, and a full-
length α1β1γ1 complex [32]. Other analyses also suggested that PT-1 bound in the cleft between 
the KD and AID, causing a conformational change that relieves auto-inhibition [32]. However, in 
our incubated mouse muscle system PT-1 did not activate all AMPK complexes. Although it 
activated all γ1-containing complexes (containing α1 or α2, with either β1 or β2), it failed to 
activate the a2β2γ3 complex, which has previously been proposed to play a special role in 
increasing glucose transport in response to muscle contraction, based on the requirement of α2, β2 
and γ3 for AICAR-stimulated glucose transport [2;25;39].  
Since it was difficult to envisage how the effect of an activator that bound between the KD and the 
AID would be affected by the identity of the γ subunit, we re-investigated the mechanism by which 
PT-1 activated AMPK. We constructed HEK-293 cells expressing either wild type human γ1 or γ1 
with an R299G mutation. This mutation abolishes the positive charge on a side chain involved in 
the interaction with the phosphate group of AMP in the critical regulatory site on the γ subunits, site 
3 [45-47]. We expected that the R299G mutation in γ1, like the equivalent mutation in γ2 [21], 
would render AMPK insensitive to drugs that activate AMPK by inhibiting mitochondrial ATP 
synthesis and increasing cellular AMP. This was indeed confirmed using treatment with berberine, 
a known inhibitor of Complex I of the respiratory chain [43]. However, to our surprise, PT-1 failed 
to fully activate AMPK in cells expressing the RG mutation, and also increased cellular ADP:ATP 
and AMP:ATP ratios, suggesting that it acted by increasing cellular AMP and/or ADP. In addition, 
over the same concentration range PT-1 inhibited cellular oxygen uptake. Since the uncoupler 
dinitrophenol failed to reverse the inhibition of oxygen uptake using the highest concentrations of 
PT-1, the effect on oxygen uptake appears to be due to inhibition of the respiratory chain, rather 
than the mitochondrial ATP synthase. In the cells expressing the RG mutation, there did appear to 
be a very small residual activation of AMPK, and perhaps also increased Thr172 phosphorylation, 
by PT-1 (Fig. 5C/D), indicating that PT-1 might be acting by another minor mechanism in addition 
to its effects on cellular AMP and ADP. However, we could find no evidence (Fig. 7) that PT-1 
directly activated AMPK in cell-free assays as suggested by Pang et al [32], using either a KD:AID 
(1-333) construct of human AMPK-α1, or native AMPK purified from rat liver, which is a mixture 
of α1β1γ1 and α2β1γ1 heterotrimers. All that we observed was an inhibition at concentrations 
above 10 µM; since this also occurred with the 1-312 construct that contained only the kinase 
domain, this was likely to be due to binding of PT-1 to the catalytic site. 
Since our results were very different to those reported previously [20], we analyzed our commercial 
preparation of PT1 by mass spectrometry and NMR spectroscopy. The results were identical with 
those reported previously, indicating that the compound was, as expected, a mixture of the amino 
and imino tautomers [48]; the purity was estimated to be >98%. At present, the discrepancies 
between our results and previous results with PT-1 [32] are difficult to explain. The original authors 
recently reported that PT-1 was not an effective AMPK activator in vivo due to its poor bio-
availability, and have developed a new activator, C24, which appears to bind between the KD and 
AID [28;48]. Although apparently derived by systematic modifications of PT-1, its structure is in 
fact quite different. 
Although our results showed that PT-1 was selective for γ1- rather than γ3-containing complexes in 
mouse skeletal muscle incubated ex vivo, in HEK-293 cells expressing γ1-, γ2- or γ3-complexes it 
activated all three complexes, and increased the phosphorylation of all three on Thr172. Thus, the 
apparent selectivity of PT-1 for γ1 over γ3 complexes in skeletal muscle appears to be a specific 
feature of that tissue, rather than being an intrinsic feature of the γ subunit isoforms themselves. 
One potential explanation is that AMPK complexes containing γ1 or γ3 are targeted to distinct 
subcellular compartments in skeletal muscle. Inhibition of the respiratory chain (and hence 
mitochondrial ATP synthesis) might increase AMP:ATP and/or ADP:ATP ratios only in the 
compartment where γ1 complexes are localized, whereas increased turnover of ATP during muscle 
contraction may increase AMP:ATP and/or ADP:ATP ratios only in the compartment where the 
α2β2γ3 complex is localized, explaining why this is the only complex rapidly activated by high 
intensity exercise [4]. In fact, previous studies support the idea that the γ isoforms may target 
AMPK heterotrimers to different subcellular compartments [15;34;35]. In mouse skeletal muscle, 
γ1 complexes have been reported to be localized to the Z-disks, and γ3 complexes to the I-band [34].  
 
Irrespective of the explanation for selective activation of γ1- over γ3-containing complexes in 
muscle, our data indicate that PT-1 can be used to distinguished between substrates of γ1 and γ3 
AMPK in mouse skeletal muscle. For instance, Ser212 on ACC2 is predominantly a target of 
AMPK complexes containing γ3 rather than γ1. The major γ3-containing complex in both mouse 
and human muscle is α2β2γ3 [4;41]. Our results are consistent with studies of exercise in humans, 
where short-duration, high-intensity cycling increased the activity of the α2β2γ3 complex but not 
γ1-containing complexes in vastus lateralis, correlating with phosphorylation of ACC2 on the site 
equivalent to Ser212 [4;42]. A similar validation has been made for TBC1D1 Ser231 [10] and we 
have unpublished data showing that 15 min of high-intensity bicycle exercise in humans, expected 
to activate predominantly the α2β2γ3 complex, potently stimulates Raptor Ser792 phosphorylation 
(M. Kleinert, T.E. Jensen and E.A. Richter – unpublished observation). In contrast, our data indicate 
that the autophagy-regulating AMPK site on ULK1 Ser555 might be a γ1 AMPK site, which 
intuitively seems consistent with the delayed increase in γ1 AMPK activity during human exercise. 
Importantly, an earlier study reported that over-expression of an activating R70Q γ1 AMPK 
mutation in mouse muscle increased phosphorylation of Ser212 on ACC2 [3], similar to over-
expression of an activated γ3 mutant (R225Q) [2]. Since acute activation of endogenous γ1 
complexes did not increase ACC2 phosphorylation in the present study, this suggests that the ACC2 
phosphorylation observed with the activated γ1 mutant may have been an artefact, perhaps because 
the over-expressed γ1 complex locates to a subcellular compartment where endogenous γ1 
complexes are not found.  
 
In summary, PT-1 selectively stimulated the activity of AMPK complexes containing γ1, but not γ3 
in mouse skeletal muscle, and also failed to promote ACC2 phosphorylation, TBC1D1 
phosphorylation and glucose transport. However, this selectivity is a specific feature of skeletal 
muscle, since no isoform selectivity was observed when γ1, γ2 and γ3 were expressed in HEK-293 
cells. Despite this, this compound may aid in identifying new substrates and roles of γ1 complexes 
in skeletal muscle. We also report that PT-1 activates AMPK in HEK-293 cells (and presumably 
also therefore in skeletal muscle) not by relieving inhibition of the kinase domain by the auto-
inhibitory domain as previously proposed, but by inhibiting the mitochondrial respiratory chain and 
increasing cellular AMP and/or ADP levels. 
Acknowledgements  
We thank Janne R. Hingst for allowing us to verify the TBC1D1 Ser231 antibody on his 
immunoprecipitations of TBC1D1 and TBC1D4 and Jesper B. Birk for measuring AMPK activity 
in the mouse muscle lysates.  
Author contribution 
TEJ, EAR, DGH designed research, TEJ, FAR, LS, MK and JRK performed research, TEJ, FAR 
analyzed data, TEJ and DGH wrote the paper with input from all co-authors.  
Funding  
This study was supported by grants from the Weimann foundation, NovoNordisk Foundation and 
Danish Research Council to TEJ and by grants to EAR from the Danish Medical Research Council, 
The Lundbeck Foundation and NovoNordisk Foundation. FAR and DGH were supported by a 
Senior Investigator Award from the Wellcome Trust. 
REFERENCES 
	  
	   1	  	   Arad,	  M.,	  Seidman,	  C.	  E.,	  and	  Seidman,	  J.	  G.	  (2007)	  Circ.Res.	  100,	  474-­‐488	  
	   2	  	   Barnes,	  B.	  R.,	  Marklund,	  S.,	  Steiler,	  T.	  L.,	  Walter,	  M.,	  Hjalm,	  G.,	  Amarger,	  V.,	  Mahlapuu,	  M.,	  Leng,	  Y.,	  
Johansson,	   C.,	   Galuska,	   D.,	   Lindgren,	   K.,	   Abrink,	  M.,	   Stapleton,	   D.,	   Zierath,	   J.	   R.,	   and	   Andersson,	   L.	  
(2004)	  J.Biol.Chem.	  279,	  38441-­‐38447	  
	   3	  	   Barre,	   L.,	  Richardson,	  C.,	  Hirshman,	  M.	  F.,	  Brozinick,	   J.,	   Fiering,	  S.,	  Kemp,	  B.	  E.,	  Goodyear,	   L.	   J.,	  and	  
Witters,	  L.	  A.	  (2007)	  Am	  J	  Physiol	  Endocrinol	  Metab	  292,	  E802-­‐E811	  
	   4	  	   Birk,	  J.	  B.	  and	  Wojtaszewski,	  J.	  F.	  (2006)	  J	  Physiol	  577,	  1021-­‐1032	  
	   5	  	   Carling,	  D.,	  Thornton,	  C.,	  Woods,	  A.,	  and	  Sanders,	  M.	  J.	  (2012)	  Biochem.J.	  445,	  11-­‐27	  
	   6	  	   Cheung,	  P.	  C.,	  Salt,	  I.	  P.,	  Davies,	  S.	  P.,	  Hardie,	  D.	  G.,	  and	  Carling,	  D.	  (2000)	  Biochem.J	  346	  Pt	  3,	  659-­‐669	  
	   7	  	   Corton,	  J.	  M.,	  Gillespie,	  J.	  G.,	  Hawley,	  S.	  A.,	  and	  Hardie,	  D.	  G.	  (1995)	  Eur.J.Biochem.	  229,	  558-­‐565	  
	   8	  	   Crute,	  B.	  E.,	   Seefeld,	  K.,	  Gamble,	   J.,	  Kemp,	  B.	  E.,	   and	  Witters,	   L.	  A.	   (1998)	   J.Biol.Chem.	  273,	   35347-­‐
35354	  
	   9	  	   Davies,	  S.	  P.,	  Carling,	  D.,	  and	  Hardie,	  D.	  G.	  (1989)	  Eur.J.Biochem.	  186,	  123-­‐128	  
	   10	  	   Frosig,	  C.,	  Pehmoller,	  C.,	  Birk,	  J.	  B.,	  Richter,	  E.	  A.,	  and	  Wojtaszewski,	  J.	  F.	  (2010)	  J.Physiol	  588,	  4539-­‐
4548	  
	   11	  	   Fullerton,	  M.	  D.,	  Galic,	  S.,	  Marcinko,	  K.,	  Sikkema,	  S.,	  Pulinilkunnil,	  T.,	  Chen,	  Z.	  P.,	  O'Neill,	  H.	  M.,	  Ford,	  
R.	   J.,	   Palanivel,	   R.,	   O'Brien,	   M.,	   Hardie,	   D.	   G.,	   Macaulay,	   S.	   L.,	   Schertzer,	   J.	   D.,	   Dyck,	   J.	   R.,	   van	  
Denderen,	  B.	  J.,	  Kemp,	  B.	  E.,	  and	  Steinberg,	  G.	  R.	  (2013)	  Nat.Med.	  19,	  1649-­‐1654	  
	   12	  	   Gollob,	  M.	  H.,	  Seger,	  J.	  J.,	  Gollob,	  T.	  N.,	  Tapscott,	  T.,	  Gonzales,	  O.,	  Bachinski,	  L.,	  and	  Roberts,	  R.	  (2001)	  
Circulation	  104,	  3030-­‐3033	  
	   13	  	   Goransson,	  O.,	  McBride,	  A.,	  Hawley,	  S.	  A.,	  Ross,	  F.	  A.,	  Shpiro,	  N.,	  Foretz,	  M.,	  Viollet,	  B.,	  Hardie,	  D.	  G.,	  
and	  Sakamoto,	  K.	  (2007)	  J.Biol.Chem.	  282,	  32549-­‐32560	  
	   14	  	   Gowans,	  G.	  J.,	  Hawley,	  S.	  A.,	  Ross,	  F.	  A.,	  and	  Hardie,	  D.	  G.	  (2013)	  Cell	  Metab	  18,	  556-­‐566	  
	   15	  	   Gregor,	  M.,	  Zeold,	  A.,	  Oehler,	  S.,	  Marobela,	  K.	  A.,	  Fuchs,	  P.,	  Weigel,	  G.,	  Hardie,	  D.	  G.,	  and	  Wiche,	  G.	  
(2006)	  J.Cell	  Sci.	  119,	  1864-­‐1875	  
	   16	  	   Hardie,	  D.	  G.	  (2013)	  Diabetes	  62,	  2164-­‐2172	  
	   17	  	   Hardie,	  D.	  G.	  (2014)	  Annu.Rev.Nutr.	  34,	  31-­‐55	  
	   18	  	   Hardie,	  D.	  G.	  and	  Ashford,	  M.	  L.	  (2014)	  Physiology	  (Bethesda.)	  29,	  99-­‐107	  
	   19	  	   Hardie,	  D.	  G.,	  Salt,	  I.	  P.,	  and	  Davies,	  S.	  P.	  (2000)	  Methods	  Mol.Biol.	  99,	  63-­‐74	  
	   20	  	   Hawley,	  S.	  A.,	  Davison,	  M.,	  Woods,	  A.,	  Davies,	  S.	  P.,	  Beri,	  R.	  K.,	  Carling,	  D.,	  and	  Hardie,	  D.	  G.	   (1996)	  
J.Biol.Chem.	  271,	  27879-­‐27887	  
	   21	  	   Hawley,	  S.	  A.,	  Ross,	  F.	  A.,	  Chevtzoff,	  C.,	  Green,	  K.	  A.,	  Evans,	  A.,	  Fogarty,	  S.,	  Towler,	  M.	  C.,	  Brown,	  L.	  J.,	  
Ogunbayo,	  O.	  A.,	  Evans,	  A.	  M.,	  and	  Hardie,	  D.	  G.	  (2010)	  Cell	  Metab	  11,	  554-­‐565	  
	   22	  	   Hunter,	  R.	  W.,	  Foretz,	  M.,	  Bultot,	  L.,	  Fullerton,	  M.	  D.,	  Deak,	  M.,	  Ross,	  F.	  A.,	  Hawley,	  S.	  A.,	  Shpiro,	  N.,	  
Viollet,	  B.,	  Barron,	  D.,	  Kemp,	  B.	  E.,	  Steinberg,	  G.	  R.,	  Hardie,	  D.	  G.,	  and	  Sakamoto,	  K.	  (2014)	  Chem.Biol.	  
21,	  866-­‐879	  
	   23	  	   Jensen,	  T.	  E.,	  Leutert,	  R.,	  Rasmussen,	  S.	  T.,	  Mouatt,	  J.	  R.,	  Christiansen,	  M.	  L.,	  Jensen,	  B.	  R.,	  and	  Richter,	  
E.	  A.	  (2012)	  PLoS.ONE.	  7,	  e31054	  
	   24	  	   Jorgensen,	  S.	  B.,	  Nielsen,	  J.	  N.,	  Birk,	  J.	  B.,	  Olsen,	  G.	  S.,	  Viollet,	  B.,	  Andreelli,	  F.,	  Schjerling,	  P.,	  Vaulont,	  
S.,	  Hardie,	  D.	  G.,	  Hansen,	  B.	  F.,	  Richter,	  E.	  A.,	  and	  Wojtaszewski,	  J.	  F.	  (2004)	  Diabetes	  53,	  3074-­‐3081	  
	   25	  	   Jørgensen,	  S.	  B.,	  Viollet,	  B.,	  Andreelli,	  F.,	  Frosig,	  C.,	  Birk,	  J.	  B.,	  Schjerling,	  P.,	  Vaulont,	  S.,	  Richter,	  E.	  A.,	  
and	  Wojtaszewski,	  J.	  F.	  P.	  (2004)	  J.Biol.Chem.	  279,	  1070-­‐1079	  
	   26	  	   Kim,	  M.,	  Hunter,	  R.	  W.,	  Garcia-­‐Menendez,	  L.,	  Gong,	  G.,	  Yang,	  Y.	  Y.,	  Kolwicz,	  S.	  C.,	  Jr.,	  Xu,	  J.,	  Sakamoto,	  
K.,	  Wang,	  W.,	  and	  Tian,	  R.	  (2014)	  Circ.Res.	  114,	  966-­‐975	  
	   27	  	   Lai,	  Y.	  C.,	  Kviklyte,	  S.,	  Vertommen,	  D.,	  Lantier,	  L.,	  Foretz,	  M.,	  Viollet,	  B.,	  Hallen,	  S.,	  and	  Rider,	  M.	  H.	  
(2014)	  Biochem.J.	  460,	  363-­‐375	  
	   28	  	   Li,	  Y.	  Y.,	  Yu,	  L.	  F.,	  Zhang,	  L.	  N.,	  Qiu,	  B.	  Y.,	  Su,	  M.	  B.,	  Wu,	  F.,	  Chen,	  D.	  K.,	  Pang,	  T.,	  Gu,	  M.,	  Zhang,	  W.,	  Ma,	  
W.	  P.,	  Jiang,	  H.	  W.,	  Li,	  J.	  Y.,	  Nan,	  F.	  J.,	  and	  Li,	  J.	  (2013)	  Toxicol.Appl.Pharmacol.	  273,	  325-­‐334	  
	   29	  	   Merry,	  T.	  L.,	  Steinberg,	  G.	  R.,	  Lynch,	  G.	  S.,	  and	  McConell,	  G.	  K.	  (2010)	  Am.J.Physiol	  Endocrinol.Metab	  
298,	  E577-­‐E585	  
	   30	  	   Mu,	  J.,	  Brozinick,	  J.	  T.,	  Jr.,	  Valladares,	  O.,	  Bucan,	  M.,	  and	  Birnbaum,	  M.	  J.	  (2001)	  Mol.Cell	  7,	  1085-­‐1094	  
	   31	  	   Pang,	  T.,	  Xiong,	  B.,	  Li,	  J.	  Y.,	  Qiu,	  B.	  Y.,	  Jin,	  G.	  Z.,	  Shen,	  J.	  K.,	  and	  Li,	  J.	  (2007)	  J	  Biol.Chem.	  282,	  495-­‐506	  
	   32	  	   Pang,	  T.,	  Zhang,	  Z.	  S.,	  Gu,	  M.,	  Qiu,	  B.	  Y.,	  Yu,	  L.	  F.,	  Cao,	  P.	  R.,	  Shao,	  W.,	  Su,	  M.	  B.,	  Li,	  J.	  Y.,	  Nan,	  F.	  J.,	  and	  
Li,	  J.	  (2008)	  J.Biol.Chem.	  283,	  16051-­‐16060	  
	   33	  	   Pehmoller,	   C.,	   Treebak,	   J.	   T.,	   Birk,	   J.	   B.,	   Chen,	   S.,	  MacKintosh,	   C.,	   Hardie,	   D.	   G.,	   Richter,	   E.	   A.,	   and	  
Wojtaszewski,	  J.	  F.	  (2009)	  Am.J.Physiol	  Endocrinol.Metab	  297,	  E665-­‐E675	  
	   34	  	   Pinter,	  K.,	  Grignani,	  R.	  T.,	  Watkins,	  H.,	  and	  Redwood,	  C.	  (2013)	  J.Muscle	  Res.Cell	  Motil.	  34,	  369-­‐378	  
	   35	  	   Pinter,	  K.,	  Jefferson,	  A.,	  Czibik,	  G.,	  Watkins,	  H.,	  and	  Redwood,	  C.	  (2012)	  Cell	  Cycle	  11,	  917-­‐921	  
	   36	  	   Scott,	  J.	  W.,	  van	  Denderen,	  B.	  J.,	  Jorgensen,	  S.	  B.,	  Honeyman,	  J.	  E.,	  Steinberg,	  G.	  R.,	  Oakhill,	  J.	  S.,	  Iseli,	  
T.	  J.,	  Koay,	  A.,	  Gooley,	  P.	  R.,	  Stapleton,	  D.,	  and	  Kemp,	  B.	  E.	  (2008)	  Chem.Biol.	  15,	  1220-­‐1230	  
	   37	  	   Steinberg,	  G.	  R.,	  Dandapani,	  M.,	  and	  Hardie,	  D.	  G.	  (2013)	  Trends	  Endocrinol.Metab	  24,	  481-­‐487	  
	   38	  	   Steinberg,	  G.	  R.	  and	  Kemp,	  B.	  E.	  (2009)	  Physiol	  Rev.	  89,	  1025-­‐1078	  
	   39	  	   Steinberg,	   G.	   R.,	   O'Neill,	   H.	   M.,	   Dzamko,	   N.	   L.,	   Galic,	   S.,	   Naim,	   T.,	   Koopman,	   R.,	   Jorgensen,	   S.	   B.,	  
Honeyman,	  J.,	  Hewitt,	  K.,	  Chen,	  Z.	  P.,	  Schertzer,	  J.	  D.,	  Scott,	  J.	  W.,	  Koentgen,	  F.,	  Lynch,	  G.	  S.,	  Watt,	  M.	  
J.,	  van	  Denderen,	  B.	  J.,	  Campbell,	  D.	  J.,	  and	  Kemp,	  B.	  E.	  (2010)	  J.Biol.Chem.	  285,	  37198-­‐37209	  
	   40	  	   Taylor,	  E.	  B.,	  An,	  D.,	  Kramer,	  H.	  F.,	  Yu,	  H.,	  Fujii,	  N.	  L.,	  Roeckl,	  K.	  S.,	  Bowles,	  N.,	  Hirshman,	  M.	  F.,	  Xie,	  J.,	  
Feener,	  E.	  P.,	  and	  Goodyear,	  L.	  J.	  (2008)	  J.Biol.Chem.	  283,	  9787-­‐9796	  
	   41	  	   Treebak,	  J.	  T.,	  Birk,	  J.	  B.,	  Hansen,	  B.	  F.,	  Olsen,	  G.	  S.,	  and	  Wojtaszewski,	   J.	  F.	   (2009)	  Am.J.Physiol	  Cell	  
Physiol	  297,	  C1041-­‐C1052	  
	   42	  	   Treebak,	   J.	   T.,	   Birk,	   J.	   B.,	   Rose,	   A.	   J.,	   Kiens,	   B.,	   Richter,	   E.	   A.,	   and	  Wojtaszewski,	   J.	   F.	   (2006)	   Am	   J	  
Physiol	  Endocrinol	  Metab	  00380	  
	   43	  	   Turner,	  N.,	  Li,	  J.	  Y.,	  Gosby,	  A.,	  To,	  S.	  W.,	  Cheng,	  Z.,	  Miyoshi,	  H.,	  Taketo,	  M.	  M.,	  Cooney,	  G.	  J.,	  Kraegen,	  
E.	  W.,	  James,	  D.	  E.,	  Hu,	  L.	  H.,	  Li,	  J.,	  and	  Ye,	  J.	  M.	  (2008)	  Diabetes	  57,	  1414-­‐1418	  
	   44	  	   Woods,	  A.,	  Salt,	  I.,	  Scott,	  J.,	  Hardie,	  D.	  G.,	  and	  Carling,	  D.	  (1996)	  FEBS	  Lett.	  397,	  347-­‐351	  
	   45	  	   Xiao,	  B.,	  Heath,	  R.,	  Saiu,	  P.,	   Leiper,	  F.	  C.,	   Leone,	  P.,	   Jing,	  C.,	  Walker,	  P.	  A.,	  Haire,	   L.,	  Eccleston,	   J.	  F.,	  
Davis,	  C.	  T.,	  Martin,	  S.	  R.,	  Carling,	  D.,	  and	  Gamblin,	  S.	  J.	  (2007)	  Nature	  449,	  496-­‐500	  
	   46	  	   Xiao,	  B.,	  Sanders,	  M.	  J.,	  Carmena,	  D.,	  Bright,	  N.	  J.,	  Haire,	  L.	  F.,	  Underwood,	  E.,	  Patel,	  B.	  R.,	  Heath,	  R.	  B.,	  
Walker,	   P.	   A.,	   Hallen,	   S.,	   Giordanetto,	   F.,	   Martin,	   S.	   R.,	   Carling,	   D.,	   and	   Gamblin,	   S.	   J.	   (2013)	  
Nat.Commun.	  4,	  3017	  
	   47	  	   Xiao,	  B.,	  Sanders,	  M.	  J.,	  Underwood,	  E.,	  Heath,	  R.,	  Mayer,	  F.	  V.,	  Carmena,	  D.,	   Jing,	  C.,	  Walker,	  P.	  A.,	  
Eccleston,	  J.	  F.,	  Haire,	  L.	  F.,	  Saiu,	  P.,	  Howell,	  S.	  A.,	  Aasland,	  R.,	  Martin,	  S.	  R.,	  Carling,	  D.,	  and	  Gamblin,	  
S.	  J.	  (2011)	  Nature	  472,	  230-­‐233	  
	   48	  	   Yu,	  L.	  F.,	  Li,	  Y.	  Y.,	  Su,	  M.	  B.,	  Zhang,	  M.,	  Zhang,	  W.,	  Zhang,	  L.	  N.,	  Pang,	  T.,	  Zhang,	  R.	  T.,	  Liu,	  B.,	  Li,	  J.	  Y.,	  Li,	  
J.,	  and	  Nan,	  F.	  J.	  (2013)	  ACS	  Med.Chem.Lett.	  4,	  475-­‐480	  
	   49	  	   Zadra,	  G.,	   Photopoulos,	   C.,	   Tyekucheva,	   S.,	   Heidari,	   P.,	  Weng,	  Q.	   P.,	   Fedele,	  G.,	   Liu,	  H.,	   Scaglia,	  N.,	  
Priolo,	  C.,	  Sicinska,	  E.,	  Mahmood,	  U.,	  Signoretti,	  S.,	  Birnberg,	  N.,	  and	  Loda,	  M.	  (2014)	  EMBO	  Mol.Med.	  
6,	  519-­‐538	  
	  
 
  
Figure legends 
Figure 1. PT-1 dose-dependently increases AMPK Thr172 phosphorylation but slightly suppresses 
muscle glucose transport. A) C57BL/6 soleus and EDL muscles were incubated with 0, 40, 80 and 
100 µM PT-1 for 1h after which AMPK Thr172 was measured by western blotting. Actin was used 
as a loading control. B) Representative blots and quantifications of AMPK Thr172 in soleus and 
EDL muscle from wild type vs. kinase-dead (KD) AMPK mice C) 2DG transport in the same 
muscles. */*** p<0.05/0.001 ANOVA main-effect compared to basal, ### p < 0.001 genotype-
effect. n = 2 for optimization and n= 4 for wild type vs. kinase-dead AMPK mice. Results are mean 
± SE. 
Figure 2. PT-1 stimulates AMPK Thr172, but not ACC2 or TBC1D1 phosphorylation, whereas 
AICAR stimulates all. Western blotting were performed on C57BL/6 soleus and EDL muscles 
stimulated with PT-1 (100 µM, 1h), AICAR (2 mM, 1h) or combined PT-1+AICAR treatment to 
assess A) AMPK Thr172, B) ACC2 Ser212, C) TBC1D1 Ser231 in EDL and D) TBC1D1 Thr590 
in EDL. E) Glycogen synthase (GS) Ser8 in soleus and EDL. Representative blots are shown in F). 
To verify the TBC1D1 Ser231 antibody in G), the top band of the doublet recognized by the 
phospho-Ser231 antibody in AICAR-stimulated mouse EDL was shown to align with total 
TBC1D1 and H) to be depleted by immunoprecipitation with total TBC1D1 but not TBC1D4. I) 
Immunoblot of ACC1, ACC2 and ACC1/2 Ser79/Ser212 in mouse muscle and liver as indicated. J) 
The GS Ser8 phosphorylation was reduced in resting kinase-dead (KD) AMPK overexpressing 
soleus muscles compared to wild type. */**/***p <0.05/0.01/0.001 T-test or Tukey post hoc 
difference compared to control, ǂ/ǂǂǂ p<0.05/0.001 Tukey post hoc difference compared to AICAR. 
n=8 for PT+AICAR experiments, n=6 for wild type vs. kinase-dead (KD) AMPK muscles. Results 
are mean ± SE. 
Figure 3. In contrast to AICAR, PT-1 does not stimulate muscle glucose transport. C57BL/6 soleus 
and EDL muscles were stimulated with PT-1 (100 µM, 1h), AICAR (2 mM, 1h) or combined PT-
1+AICAR treatment after which 2-deoxyglucose transport was measured in A) soleus and B) EDL. 
*** p < 0.001 Tukey post hoc difference compared to Basal. n=8. Results are mean ± SE. 
Figure 4. PT-1 increases γ1 AMPK, but not α2β2γ3 AMPK associated kinase activity in vitro, 
whereas AICAR stimulates all complexes. AMPK complexes were sequentially 
immunoprecipitated from C57BL/6 soleus and EDL muscles (n=8) stimulated with PT-1 (100 µM, 
1h), AICAR (2 mM, 1h) or combined PT-1+AICAR treatment to isolate the activities of A) α1β1γ1 
and α1β2γ1, B) α2β1γ1 and α2β2γ1, C) α2β2γ3 AMPK. D) Immunoblots and coomassie (loading 
control) of Raptor Ser792 and ULK1 Ser555 phosphorylation in wild type and kinase-dead (KD) 
AMPK soleus and EDL ± PT-1 (n=5-7), E) ± AICAR (n=3). E) Quantification of ULK1 Ser555 
phosphorylation and F) Quantification of Raptor Ser792 phosphorylation. */**/*** p 
<0.05/0.01/0.001 Tukey post hoc or T-test difference. †/††/††† p <0.05/0.01/0.001 ANOVA main-
effect or interaction (if only above stimulated bars). Results are mean ± SE. 
Figure 5. PT-1 fails to fully activate AMPK in a cell line expressing an AMP-insensitive AMPK-γ1 
mutant. (A) Characterization by Western blotting of parental HEK-293 cells and cells stably 
expressing either the wild type (WT) or the R299G mutant (RG) of AMPK-γ1. Duplicate cell 
lysates were blotted with the indicated antibodies. (B) Effect of incubating WT or RG cells with 
increasing concentrations of berberine for 1 hr. AMPK was immunoprecipitated using anti-FLAG 
antibody and immunoprecipitates assays for AMPK activity. Results are expressed as % of the 
activity in a control without berberine. Mean values significantly different from controls without 
berberine (1-way ANOVA with Dunnett’s multiple comparison test, n = 4) are indicated: *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001. (C) As (B), but replacing berberine by PT-1 (n = 3). (D) 
Effect of PT-1 (n = 3) on phosphorylation of Thr172; Western blots for total AMPK-α and FLAG 
are also shown to confirm equal loadings. 
Figure 6. Effect of PT-1 on cellular ADP:ATP and AMP:ATP ratios, and cellular oxygen uptake. 
(A) Effect on adenine nucleotide ratios; cells were incubated with the indicated concentration of 
PT-1 for 1hr, perchloric acid extracts prepared, and ADP:ATP ratios estimated by capillary 
electrophoresis [26]. AMP:ATP ratios were calculated from ADP:ATP by assuming that the 
adenylate kinase reaction was at equilibrium, so that AMP:ATP = (ADP:ATP)2 [29]. Results are 
mean ± SD (n = 2). (C) Effect on oxygen uptake; cells were grown in Seahorse™ plates and the 
baseline rate of oxygen uptake measured in the Seahorse™ XF24 Extracellular Flux Analyzer. At 
the point shown by the first vertical arrow, PT1 (indicated concentrations), phenformin (3 mM) or 
vehicle (DMSO) were added and oxygen uptake measured for 75 min. Dinitrophenol (DNP, 100 
µM) was then added and measurement of oxygen uptake continued for a further 15 min. results are 
expressed as percentages of baseline oxygen uptake as mean ± SD (n =3, DMSO/phenformin; n = 4, 
PT-1). 
Figure 7. Effect of PT-1 on the kinase activity in cell-free assays of bacterially expressed constructs 
derived from rat AMPK-α1 and native AMPK from rat liver. (A) Effect of increasing 
concentrations of PT-1 on the activity of constructs containing the KD and AID (1-333) and the KD 
only (1-312). (B) Effect of increasing concentrations of PT-1, and of AMP (200 µM) and A-769662 
(1 µM) on the activity of AMPK purified from rat liver. 
Figure 8. Phenformin and PT-1 are equally effective in stimulating the activity of AMPK 
complexes containing γ1, γ2 and γ3 in HEK-293 cells. (A) Characterization by Western blotting of 
parental HEK-293 cells and cells stably expressing either wild type -γ1, -γ2 or -γ1. Duplicate cell 
lysates were blotted with the indicated antibodies. (B) Bar chart showing AMPK activity measured 
in anti-FLAG immunoprecipitates of cells treated for 1 hr with phenformin (10 mM) or PT-1 (100 
µM). Results are mean ± SD (n = 3, separate cell incubations), and results that are significantly 
different from the relevant control without phenformin or PT-1 (1-way ANOVA with Sidak’s 
multiple comparison test of selected datasets) are shown with asterisks (**** p<0.0001). The lower 
panels show Western blots of duplicate dishes of cells probed using anti-pT172 (top), anti-AMPK-α 
(centre) or anti-FLAG (bottom). 
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